Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
4 Medical Product Stocks to Buy From a Prospective Industry
10:45am, Wednesday, 04'th Dec 2024
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable fac
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 26'th Nov 2024
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
09:05am, Tuesday, 05'th Nov 2024
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-i
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
11:50am, Friday, 01'st Nov 2024
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
02:16pm, Thursday, 31'st Oct 2024
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communicati
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
08:46am, Thursday, 31'st Oct 2024
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
06:30am, Thursday, 31'st Oct 2024
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
07:00am, Thursday, 17'th Oct 2024
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
12:35pm, Thursday, 12'th Sep 2024
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
07:00am, Wednesday, 11'th Sep 2024
CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
07:00am, Thursday, 05'th Sep 2024
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
10:18am, Tuesday, 27'th Aug 2024
Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 tria
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
05:50pm, Tuesday, 06'th Aug 2024
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Bi
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
11:46am, Friday, 02'nd Aug 2024
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
01:42pm, Thursday, 01'st Aug 2024
On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to
